The initiative will provide practical insights into understanding of obesity pathophysiology and its management.

The Obesity Gurukul initiative will train over 20,000 healthcare professionals across India through a hybrid education model ...

Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...

Eli Lilly’s Mounjaro weight-loss drug. Photo: Bloomberg News The obesity duopoly has been pierced as Amgen AMGN -0.10% positions itself to have a drug on the market in a few years.

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug market. Read the full stock analysis here.

"KeyBioscience and Eli Lilly extend partnership for obesity treatments" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

Laekna, Inc. has entered into a clinical collaboration with Eli Lilly to develop LAE102, a promising drug candidate aimed at treating obesity.

InnovationRx: Eli Lilly Has Stockpiled Nearly $550 Million Of Its Next Obesity Drug By Amy Feldman, Forbes Staff and Alex Knapp, Forbes Staff.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio.

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b trial, according to data published in The New England Journal of Medicine ...

The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting drug it has developed to create a new standard of patient care for ...

Eli Lilly has thinned its pipeline in two critical areas, axing clinical-phase Alzheimer’s and obesity candidates as part of its quarterly clear-out.